Amber Therapeutics

Amber Therapeutics was founded in 2021 by Aidan Crawley, Tim Denison, Stefan De Wachter, and Charles Knowles with a mission to develop breakthrough neuromodulation therapies for areas of unmet clinical need. Its lead program, Amber-UI, is the world's first fully implantable, closed-loop adaptive neuromodulation therapy targeting the pudendal nerve to treat mixed urinary incontinence — a condition affecting 40 million women in the US. The company completed successful first-in-human implants in the AURA-2 feasibility study and is advancing toward US FDA approval.